Transcode Therapeutics, Inc. RNAZ
Transcode Therapeutics, Inc. (Nasdaq: RNAZ) is an oncology drug developer. Its lead program, TTX-MC138, is in Phase 1 for advanced solid tumors / metastatic cancers (miR-10b overexpressing); Phase 2a in ctDNA-positive MRD colorectal cancer.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TTX-MC138 - Phase 2a (PRE-I-SPY, with Quantum Leap) | ctDNA-positive colorectal cancer with minimal residual disease | RNA (siRNA/ASO/mRNA) | Phase 2 |
| TTX-MC138 - Phase I/II dose escalation (Phase 1a complete; 3 patients remain on trial) | advanced solid tumors | RNA (siRNA/ASO/mRNA) | Phase 1 |
| Seviprotimut-L (acquired from Polynoma) | adjuvant stage IIB/IIC melanoma | vaccine | Pre-clinical |
| Genetically engineered oncolytic adenovirus program (Unleash license) | cancer | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.